jeudi 28 mai 2020

Onco Actu du 28 mai 2020


1. BIOLOGIE



Pregnancy reprograms breast cells, reducing cancer risk [Cold Spring Harbor Laboratory]











Gene inactivation of PTEN drives cancer predisposition [Medical XPress]











1.1 BIOLOGIE - GÉNOME



International gnomAD Consortium releases its first major studies of human genetic variation [Broad Institute]











A milestone in human genetics highlights diversity gaps [Nature]










GnomAD Consortium Details Range of Human Genetic Variation From Large Dataset [Genome Web]











5. TRAITEMENTS



Take lessons from cancer evolution to the clinic [Nature]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Gilead pens $2B Arcus pact for immuno-oncology targets of the past and future [Fierce Biotech]











Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact [Xconomy]











Gilead puts $375M into Arcus in latest push to broaden cancer business [Biopharma Dive]











Gilead leases partner rights to TIGIT, PD-1 in a $2B deal with Arcus. Now comes the hard part [EndPoints]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



New Cancer Immunotherapy Targeting Myeloid Cells Slows Tumor Growth [Penn Medicine]











New “Blueprint” of Exhausted T Cell Lifespan Could Help Build Better Immunotherapies [Penn Medicine]











5.12.6 IMMUNOTHÉRAPIES - AMM



Bristol Myers Squibb finally gets in the frontline NSCLC game dominated by Merck, adding a second Opdivo/Yervoy-based option [EndPoints]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



NICE recommends treatment for type of small-cell lung cancer [NICE]










5.2.2 PHARMA - FUSIONS & ACQUISITIONS



In latest cancer deal, Bristol Myers Squibb's new BD chief bets $65M in search for more targets like PARP [EndPoints]











Sanofi CEO Paul Hudson has $23B burning a hole in his pocket. And here are some hints on how he plans to spend that [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



Larotrectinib for treating NTRK fusion-positive solid tumours [NICE]











5.5.10 ASCO (HÉMATO)



ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision [Fierce Biotech]











GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight [EndPoints]











5.5.2 ASCO (SEIN)



Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease [Novartis]











6.1 OBSERVATION



Study sheds light on risks of breast cancer after pre-invasive disease [Medical XPress]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



The unexpected side effect of Covid-19 [CNN]










Finding, and Curing, Cancers May Be Another Casualty of Coronavirus [NY Times]